Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy.
Biol Pharm Bull
; 36(2): 287-91, 2013.
Article
de En
| MEDLINE
| ID: mdl-23370357
ABSTRACT
Novel polycation liposomes decorated with cyclic(Cys-Arg-Gly-Asp-D-Phe) peptide (cyclicRGD)-polyethylene glycol (PEG) (RGD-PEG-polycation liposomes (PCL)) were previously developed for cancer therapy based on RNA interference. Here, we demonstrate the in vivo delivery of small interfering RNA (siRNA) to tumors by use of RGD-PEG-PCL in B16F10 melanoma-bearing mice. Pharmacokinetic data obtained by positron emission tomography showed that cholesterol-conjugated siRNA formulated in RGD-PEG-PCL markedly accumulated in the tumors. Delivered by RGD-PEG-PCL, a therapeutic cocktail of siRNAs composed of cholesterol-conjugated siRNAs for c-myc, MDM2, and vascular endothelial growth factor (VEGF) were able to significantly inhibit the growth of B16F10 melanoma both in vitro and in vivo. These data suggest that targeted delivery of siRNAs by use of RGD-PEG-PCL has considerable potential for cancer treatment.
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Mélanome expérimental
/
Petit ARN interférent
/
Facteur de croissance endothéliale vasculaire de type A
/
Protéines proto-oncogènes c-mdm2
/
Alpha-Amylases salivaires
/
Tumeurs du poumon
Limites:
Animals
Langue:
En
Journal:
Biol Pharm Bull
Sujet du journal:
BIOQUIMICA
/
FARMACOLOGIA
Année:
2013
Type de document:
Article
Pays d'affiliation:
Japon